Trial Profile
A Phase 3, Prospective, Randomized, Partially Blinded Multi-Center Study to Measure the Safety and Efficacy of NOVOCART 3D Compared ot Microfracture in the Treatment of Articular Cartilage Defects
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Autologous chondrocyte implantation (Primary)
- Indications Cartilage disorders
- Focus Therapeutic Use
- Sponsors Aesculap Biologics
- 01 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2027.
- 01 Mar 2022 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2024.
- 28 Feb 2019 According to an Aesculap Biologics media release, Ivan Wong, MD, is a principal investigator of this study at one ot the sites in Canada.